Registro:

Referencias:

• Smyth, M.J., Godfrey, D.I., Trapani, J.A., A fresh look at tumor immunosurveillance and immunotherapy (2001) Nat Immunol, 2, pp. 293-299
• Drake, C.G., Jaffee, E., Pardoll, D.M., Mechanisms of immune evasion by tumors (2006) Adv Immunol, 90, pp. 51-81
• Dunn, G.P., Old, L.J., Schreiber, R.D., The three Es of cancer immunoediting (2004) Annu Rev Immunol, 22, pp. 329-360
• Koebel, C.M., Vermi, W., Swann, J.B., Zerafa, N., Rodig, S.J., Old, L.J., Adaptive immunity maintains occult cancer in an equilibrium state (2007) Nature, 450, pp. 903-907
• Pardoll, D., Allison, J., Cancer immunotherapy: Breaking the barriers to harvest the crop (2004) Nat Med, 10, pp. 887-892
• Rosenberg, S.A., Yang, J.C., Restifo, N.P., Cancer immunotherapy: Moving beyond current vaccines (2004) Nat Med, 10, pp. 909-915
• Boon, T., Coulie, P.G., Van den Eynde, B.J., van der Bruggen, P., Human T cell responses against melanoma (2006) Annu Rev Immunol, 24, pp. 175-208
• Staveley-O'Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Induction of antigen-specific T cell anergy: An early event in the course of tumor progression (1998) Proc Natl Acad Sci USA, 95, pp. 1178-1183
• Cuenca, A., Cheng, F., Wang, H., Brayer, J., Horna, P., Gu, L., Extralymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: Dominant role of cross-tolerance to tumor antigens (2003) Cancer Res, 63, pp. 9007-9015
• Morgan, D.J., Kreuwel, H.T., Fleck, S., Levitsky, H.I., Pardoll, D.M., Sherman, L.A., Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity (1998) J Immunol, 160, pp. 643-651
• Overwijk, W.W., Theoret, M.R., Finkelstein, S.E., Surman, D.R., de Jong, L.A., Vyth-Dreese, F.A., Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells (2003) J Exp Med, 198, pp. 569-580
• Willimsky, G., Blankenstein, T., Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance (2005) Nature, 437, pp. 141-146
• Lee, P.P., Yee, C., Savage, P.A., Fong, L., Brockstedt, D., Weber, J.S., Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients (1999) Nat Med, 5, pp. 677-685
• Horna, P., Cuenca, A., Cheng, F., Brayer, J., Wang, H.W., Borrello, I., In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity (2006) Blood, 107, pp. 2871-2878
• Dalyot-Herman, N., Bathe, O.F., Malek, T.R., Reversal of CD8+ T cell ignorance and induction of anti-tumor immunity by peptide-pulsed APC (2000) J Immunol, 165, pp. 6731-6737
• Lyman, M.A., Aung, S., Biggs, J.A., Sherman, L.A., A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL (2004) J Immunol, 172, pp. 6558-6567
• Steinman, R.M., Hawiger, D., Nussenzweig, M.C., Tolerogenic dendritic cells (2003) Annu Rev Immunol, 21, pp. 685-711
• Belz, G.T., Behrens, G.M., Smith, C.M., Miller, J.F., Jones, C., Lejon, K., The CD8α+ dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens (2002) J Exp Med, 196, pp. 1099-1104
• Munn, D.H., Sharma, M.D., Lee, J.R., Jhaver, K.G., Johnson, T.S., Keskin, D.B., Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase (2002) Science, 297, pp. 1867-1870
• Almand, B., Resser, J.R., Lindman, B., Nadaf, S., Clark, J.I., Kwon, E.D., Clinical significance of defective dendritic cell differentiation in cancer (2000) Clin Cancer Res, 6, pp. 1755-1766
• Hoffmann, T.K., Muller-Berghaus, J., Ferris, R.L., Johnson, J.T., Storkus, W.J., Whiteside, T.L., Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck (2002) Clin Cancer Res, 8, pp. 1787-1793
• Pinzon-Charry, A., Ho, C.S., Laherty, R., Maxwell, T., Walker, D., Gardiner, R.A., A population of HLA-DR+ immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer (2005) Neoplasia, 7, pp. 1112-1122
• Chaux, P., Favre, N., Martin, M., Martin, F., Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats (1997) Int J Cancer, 72, pp. 619-624
• Gabrilovich, D.I., Corak, J., Ciernik, I.F., Kavanaugh, D., Carbone, D.P., Decreased antigen presentation by dendritic cells in patients with breast cancer (1997) Clin Cancer Res, 3, pp. 483-490
• Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C., Amigorena, S., Antigen presentation and T cell stimulation by dendritic cells (2002) Annu Rev Immunol, 20, pp. 621-667
• Enk, A.H., Jonuleit, H., Saloga, J., Knop, J., Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma (1997) Int J Cancer, 73, pp. 309-316
• Gerlini, G., Tun-Kyi, A., Dudli, C., Burg, G., Pimpinelli, N., Nestle, F.O., Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions (2004) Am J Pathol, 165, pp. 1853-1863
• Kim, R., Emi, M., Tanabe, K., Arihiro, K., Tumor-driven evolution of immunosuppressive networks during malignant progression (2006) Cancer Res, 66, pp. 5527-5536
• Gabrilovich, D.I., Chen, H.L., Girgis, K.R., Cunningham, H.T., Meny, G.M., Nadaf, S., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells (1996) Nat Med, 2, pp. 1096-1103
• Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells (2004) Nat Med, 10, pp. 48-54
• Cheng, F., Wang, H.W., Cuenca, A., Huang, M., Ghansah, T., Brayer, J., A critical role for Stat3 signaling in immune tolerance (2003) Immunity, 19, pp. 425-436
• Evel-Kabler, K., Song, X.T., Aldrich, M., Huang, X.F., Chen, S.Y., SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling (2006) J Clin Invest, 116, pp. 90-100
• Hartmann, E., Wollenberg, B., Rothenfusser, S., Wagner, M., Wellisch, D., Mack, B., Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer (2003) Cancer Res, 63, pp. 6478-6487
• Zou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells (2001) Nat Med, 7, pp. 1339-1346
• Munn, D.H., Sharma, M.D., Hou, D., Baban, B., Lee, J.R., Antonia, S.J., Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes (2004) J Clin Invest, 114, pp. 280-290
• Fallarino, F., Grohmann, U., Hwang, K.W., Orabona, C., Vacca, C., Bianchi, R., Modulation of tryptophan catabolism by regulatory T cells (2003) Nat Immunol, 4, pp. 1206-1212
• Zhang M, Tang H, Guo Z, An H, Zhu X, Song W, et al. Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat Immunol 2004; 5: 1124-33. [38] Kusmartsev S, Gabrilovich DI. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 2002; 51: 293-8; Bronte, V., Wang, M., Overwijk, W.W., Surman, D.R., Pericle, F., Rosenberg, S.A., Apoptotic death of CD8+ T lymphocytes after immunization: Induction of a suppressive population of Mac-1+/Gr-1+ cells (1998) J Immunol, 161, pp. 5313-5320
• Gabrilovich, D.I., Velders, M.P., Sotomayor, E.M., Kast, W.M., Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells (2001) J Immunol, 166, pp. 5398-5406
• Li, Q., Pan, P.Y., Gu, P., Xu, D., Chen, S.H., Role of immature myeloid Gr-1 + cells in the development of antitumor immunity (2004) Cancer Res, 64, pp. 1130-1139
• Terabe, M., Matsui, S., Park, J.M., Mamura, M., Noben-Trauth, N., Donaldson, D.D., Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence (2003) J Exp Med, 198, pp. 1741-1752
• Kusmartsev, S., Gabrilovich, D.I., STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion (2005) J Immunol, 174, pp. 4880-4891
• Almand, B., Clark, J.I., Nikitina, E., van Beynen, J., English, N.R., Knight, S.C., Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer (2001) J Immunol, 166, pp. 678-689
• Danna, E.A., Sinha, P., Gilbert, M., Clements, V.K., Pulaski, B.A., Ostrand-Rosenberg, S., Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease (2004) Cancer Res, 64, pp. 2205-2211
• Schmielau, J., Finn, O.J., Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients (2001) Cancer Res, 61, pp. 4756-4760
• Valenti, R., Huber, V., Filipazzi, P., Pilla, L., Sovena, G., Villa, A., Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes (2006) Cancer Res, 66, pp. 9290-9298
• Balkwill, F., Cancer and the chemokine network (2004) Nat Rev Cancer, 4, pp. 540-550
• Sica, A., Allavena, P., Mantovani, A., Cancer related inflammation: The macrophage connection (2008) Cancer Lett, 267, pp. 204-215
• Saccani, A., Schioppa, T., Porta, C., Biswas, S.K., Nebuloni, M., Vago, L., p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance (2006) Cancer Res, 66, pp. 11432-11440
• Talks, K.L., Turley, H., Gatter, K.C., Maxwell, P.H., Pugh, C.W., Ratcliffe, P.J., The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages (2000) Am J Pathol, 157, pp. 411-421
• Cramer, T., Yamanishi, Y., Clausen, B.E., Forster, I., Pawlinski, R., Mackman, N., HIF-1α is essential for myeloid cell-mediated inflammation (2003) Cell, 112, pp. 645-657
• Gordon, S., Alternative activation of macrophages (2003) Nat Rev Immunol, 3, pp. 23-35
• Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival (2004) Nat Med, 10, pp. 942-949
• Karin, M., Greten, F.R., NF-κB: Linking inflammation and immunity to cancer development and progression (2005) Nat Rev Immunol, 5, pp. 749-759
• Mantovani, A., Allavena, P., Sica, A., Balkwill, F., Cancer-related inflammation (2008) Nature, 454, pp. 436-444
• Kim, S., Takahashi, H., Lin, W.W., Descargues, P., Grivennikov, S., Kim, Y., Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis (2009) Nature, 457, pp. 102-106
• Muller, A.J., Sharma, M.D., Chandler, P.R., Duhadaway, J.B., Everhart, M.E., Johnson 3rd, B.A., Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase (2008) Proc Natl Acad Sci USA, 105, pp. 17073-17078
• Akira, S., Takeda, K., Toll-like receptor signalling (2004) Nat Rev Immunol, 4, pp. 499-511
• Reis e Sousa C. Toll-like receptors and dendritic cells: for whom the bug tolls. Semin Immunol 2004; 16: 27-34; Girart, M.V., Fuertes, M.B., Domaica, C.I., Rossi, L.E., Zwirner, N.W., Engagement of TLR3, TLR7, and NKG2D regulate IFN-γ secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12 (2007) J Immunol, 179, pp. 3472-3479
• Swann, J.B., Vesely, M.D., Silva, A., Sharkey, J., Akira, S., Schreiber, R.D., Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis (2008) Proc Natl Acad Sci USA, 105, pp. 652-656
• Wang, J.H., Manning, B.J., Wu, Q.D., Blankson, S., Bouchier-Hayes, D., Redmond, H.P., Endotoxin/lipopolysaccharide activates NF-κB and enhances tumor cell adhesion and invasion through a β1 integrindependent mechanism (2003) J Immunol, 170, pp. 795-804
• Andreani, V., Gatti, G., Simonella, L., Rivero, V., Maccioni, M., Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo (2007) Cancer Res, 67, pp. 10519-10527
• Kono, H., Rock, K.L., How dying cells alert the immune system to danger (2008) Nat Rev Immunol, 8, pp. 279-289
• Chen, C.J., Kono, H., Golenbock, D., Reed, G., Akira, S., Rock, K.L., Identification of a key pathway required for the sterile inflammatory response triggered by dying cells (2007) Nat Med, 13, pp. 851-856
• Yusuf, N., Nasti, T.H., Long, J.A., Naseemuddin, M., Lucas, A.P., Xu, H., Protective role of Toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis (2008) Cancer Res, 68, pp. 615-622
• Cavassani, K.A., Ishii, M., Wen, H., Schaller, M.A., Lincoln, P.M., Lukacs, N.W., TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events (2008) J Exp Med, 205, pp. 2609-2621
• Coffelt, S.B., Scandurro, A.B., Tumors sound the alarmin(s) (2008) Cancer Res, 68, pp. 6482-6485
• Sun, C.Q., Arnold, R., Fernandez-Golarz, C., Parrish, A.B., Almekinder, T., He, J., Human β-defensin-1, a potential chromosome 8p tumor suppressor: Control of transcription and induction of apoptosis in renal cell carcinoma (2006) Cancer Res, 66, pp. 8542-8549
• Bullard, R.S., Gibson, W., Bose, S.K., Belgrave, J.K., Eaddy, A.C., Wright, C.J., Functional analysis of the host defense peptide Human β Defensin-1: New insight into its potential role in cancer (2008) Mol Immunol, 45, pp. 839-848
• Conejo-Garcia, J.R., Benencia, F., Courreges, M.C., Kang, E., Mohamed-Hadley, A., Buckanovich, R.J., Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of VEGF-A (2004) Nat Med, 10, pp. 950-958
• Economopoulou, M., Bdeir, K., Cines, D.B., Fogt, F., Bdeir, Y., Lubkowski, J., Inhibition of pathologic retinal neovascularization by alpha-defensins (2005) Blood, 106 (12), pp. 3831-3838
• De, Y., Chen, Q., Schmidt, A.P., Anderson, G.M., Wang, J.M., Wooters, J., LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells (2000) J Exp Med, 192 (7), pp. 1069-1074
• Coffelt, S.B., Waterman, R.S., Florez, L., Honer zu Bentrup, K., Zwezdaryk, K.J., Tomchuck, S.L., Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion (2008) Int J Cancer, 122 (5), pp. 1030-1039
• Heilborn, J.D., Nilsson, M.F., Jimenez, C.I., Sandstedt, B., Borregaard, N., Tham, E., Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells (2005) Int J Cancer, 114 (5), pp. 713-719
• von Haussen, J., Koczulla, R., Shaykhiev, R., Herr, C., Pinkenburg, O., Reimer, D., The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells (2008) Lung Cancer, 59 (1), pp. 12-23
• Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y.H., Homey, B., Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide (2007) Nature, 449 (7162), pp. 564-569
• Scaffidi, P., Misteli, T., Bianchi, M.E., Release of chromatin protein HMGB1 by necrotic cells triggers inflammation (2002) Nature, 418 (6894), pp. 191-195
• Mitola, S., Belleri, M., Urbinati, C., Coltrini, D., Sparatore, B., Pedrazzi, M., Cutting edge: Extracellular high mobility group box-1 protein is a proangiogenic cytokine (2006) J Immunol, 176, pp. 12-15
• Schlueter, C., Weber, H., Meyer, B., Rogalla, P., Roser, K., Hauke, S., Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule (2005) Am J Pathol, 166, pp. 1259-1263
• van Beijnum, J.R., Dings, R.P., van der Linden, E., Zwaans, B.M., Ramaekers, F.C., Mayo, K.H., Gene expression of tumor angiogenesis dissected: Specific targeting of colon cancer angiogenic vasculature (2006) Blood, 108, pp. 2339-2348
• Ito, N., DeMarco, R.A., Mailliard, R.B., Han, J., Rabinowich, H., Kalinski, P., Cytolytic cells induce HMGB1 release from melanoma cell lines (2007) J Leukoc Biol, 81, pp. 75-83
• Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy (2007) Nat Med, 13, pp. 1050-1059
• Ellerman, J.E., Brown, C.K., de Vera, M., Zeh, H.J., Billiar, T., Rubartelli, A., Masquerader: High mobility group box-1 and cancer (2007) Clin Cancer Res, 13, pp. 2836-2848
• DeMarco, R.A., Fink, M.P., Lotze, M.T., Monocytes promote natural killer cell interferon-γ production in response to the endogenous danger signal HMGB1 (2005) Mol Immunol, 42, pp. 433-444
• Lanier, L.L., NK cell recognition (2005) Annu Rev Immunol, 23, pp. 225-274
• Bryceson, Y.T., March, M.E., Ljunggren, H.-G., Long, E.O., Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion (2006) Blood, 107, pp. 159-166
• Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M.C., Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis (2001) Annu Rev Immunol, 19, pp. 197-223
• Raulet, D.H., Interplay of natural killer cells and their receptors with the adaptive immune response (2004) Nat Immunol, 5, pp. 996-1002
• Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J.H., Lanier, L.L., Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA (1999) Science, 285, pp. 727-729
• Vivier, E., Tomasello, E., Paul, P., Lymphocyte activation via NKG2D: Towards a new paradigm in immune recognition? (2002) Curr Opin Immunol, 14, pp. 306-311
• Gasser, S., Orsulic, S., Brown, E.J., Raulet, D.H., The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor (2005) Nature, 436, pp. 1186-1190
• Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K.H., Spies, T., Broad tumor-associated expression and recognition by tumorderived gamma delta T cells of MICA and MICB (1999) Proc Natl Acad Sci USA, 96, pp. 6879-6884
• Pende, D., Rivera, P., Marcenaro, S., Chang, C.-C., Biassoni, R., Conte, R., Major histocompatibility complex class i-related chain a and UL16-binding protein expression on tumor cell lines of different histotypes: Analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity (2002) Cancer Res, 62, pp. 6178-6186
• Salih, H.R., Antropius, H., Gieseke, F., Lutz, S.Z., Kanz, L., Rammensee, H.G., Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia (2003) Blood, 102, pp. 1389-1396
• Friese, M.A., Platten, M., Lutz, S.Z., Naumann, U., Aulwurm, S., Bischof, F., MICA/NKG2D-mediated immunogene therapy of experimental gliomas (2003) Cancer Res, 63, pp. 8996-9006
• Busche, A., Goldmann, T., Naumann, U., Steinle, A., Brandau, S., Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A (2006) Hum Gene Ther, 17, pp. 135-146
• Diefenbach, A., Jensen, E.R., Jamieson, A.M., Raulet, D.H., Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity (2001) Nature, 413, pp. 165-171
• Theofilopoulos, A.N., Baccala, R., Beutler, B., Kono, D.H., Type I Interferons (α/β) in immunity and autoimmunity (2005) Ann Rev Immunol, 23, pp. 307-335
• Becknell, B., Caligiuri, M.A., Interleukin-2, interleukin-15, and their roles in human natural killer cells (2005) Adv Immunol, 86, pp. 209-239
• Colombo, M.P., Trinchieri, G., Interleukin-12 in anti-tumor immunity and immunotherapy (2002) Cytokine Growth Factor Rev, 13, pp. 155-168
• Ferlazzo, G., Pack, M., Thomas, D., Paludan, C., Schmid, D., Strowig, T., Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs (2004) Proc Natl Acad Sci USA, 101, pp. 16606-16611
• Fernandez, N.C., Lozier, A., Flament, C., Ricciardi-Castagnoli, P., Bellet, D., Suter, M., Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo (1999) Nat Med, 5, pp. 405-411
• Gerosa, F., Baldani-Guerra, B., Nisii, C., Marchesini, V., Carra, G., Trinchieri, G., Reciprocal activating interaction between natural killer cells and dendritic cells (2002) J Exp Med, 195, pp. 327-333
• Lucas, M., Schachterle, W., Oberle, K., Aichele, P., Diefenbach, A., Dendritic cells prime natural killer cells by trans-presenting interleukin 15 (2007) Immunity, 26, pp. 503-517
• Kobayashi H, Dubois S, Sato N, Sabzevari H, Sakai Y, Waldmann TA, et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 2005; 105: 721-7; Martin-Fontecha, A., Thomsen, L.L., Brett, S., Gerard, C., Lipp, M., Lanzavecchia, A., Induced recruitment of NK cells to lymph nodes provides IFN-γ for T(H)1 priming (2004) Nat Immunol, 5, pp. 1260-1265
• Adam, C., King, S., Allgeier, T., Braumuller, H., Luking, C., Mysliwietz, J., DC-NK cell cross-talk as a novel CD4+ T cell-independent pathway for antitumor CTL induction (2005) Blood, 106, pp. 338-344
• Mailliard, R.B., Son, Y.I., Redlinger, R., Coates, P.T., Giermasz, A., Morel, P.A., Dendritic cells mediate NK cell help for Th1 and CTL responses: Two-signal requirement for the induction of NK cell helper function (2003) J Immunol, 171, pp. 2366-2373
• Tosi, D., Valenti, R., Cova, A., Sovena, G., Huber, V., Pilla, L., Role of cross-talk between IFN-α-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens (2004) J Immunol, 172, pp. 5363-5370
• Terme, M., Ullrich, E., Delahaye, N.F., Chaput, N., Zitvogel, L., Natural killer cell-directed therapies: Moving from unexpected results to successful strategies (2008) Nat Immunol, 9, pp. 486-494
• Sun, J.C., Beilke, J.N., Lanier, L.L., Adaptive immune features of natural killer cells (2009) Nature, 457, pp. 557-561
• Cooper, M.A., Elliott, J.M., Keyel, P.A., Yang, L., Carrero, J.A., Yokoyama, W.M., Cytokine-induced memory-like natural killer cells (2009) Proc Natl Acad Sci USA, 106, pp. 1915-1919
• Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., Schreiber, R.D., Cancer immunoediting: From immunosurveillance to tumor escape (2002) Nat Immunol, 3, pp. 991-998
• Khong, H.T., Restifo, N.P., Natural selection of tumor variants in the generation of "tumor escape" phenotypes (2002) Nat Immunol, 3, pp. 999-1005
• Andreola, G., Rivoltini, L., Castelli, C., Huber, V., Perego, P., Deho, P., Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles (2002) J Exp Med, 195, pp. 1303-1316
• Rabinovich, G.A., Sotomayor, E., Gabrilovich, D., Immunosuppressive strategies that are mediated by tumor cells (2007) Ann Rev Immunol, 25, pp. 267-296
• Rubinstein, N., Alvarez, M., Zwirner, N.W., Toscano, M.A., Ilarregui, J.M., Bravo, A., Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege (2004) Cancer Cell, 5, pp. 241-251
• Vivier, E., Tomasello, E., Baratin, M., Walzer, T., Ugolini, S., Functions of natural killer cells (2008) Nat Immunol, 9, pp. 503-510
• Moretta, A., Marcenaro, E., Parolini, S., Ferlazzo, G., Moretta, L., NK cells at the interface between innate and adaptive immunity (2008) Cell Death Differ, 15, pp. 226-233
• Dranoff, G., Cytokines in cancer pathogenesis and cancer therapy (2004) Nat Rev Cancer, 4, pp. 11-22
• Smyth, M.J., Cretney, E., Kershaw, M.H., Hayakawa, Y., Cytokines in cancer immunity and immunotherapy (2004) Immunol Rev, 202, pp. 275-293
• Strowig T, Brilot F, Munz C. Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J Immunol 2008; 180: 7785-91. [125] Zwirner NW, Fuertes MB, Girart MV, Domaica CI, Rossi LE. Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system. Cytokine Growth Factor Rev 2007; 18: 159-70; Watson, N.F., Spendlove, I., Madjd, Z., McGilvray, R., Green, A.R., Ellis, I.O., Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients (2006) Int J Cancer, 118, pp. 1445-1452
• Oppenheim, D.E., Roberts, S.J., Clarke, S.L., Filler, R., Lewis, J.M., Tigelaar, R.E., Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance (2005) Nat Immunol, 6, pp. 928-937
• Groh, V., Wu, J., Yee, C., Spies, T., Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation (2002) Nature, 419, pp. 734-738
• Salih, H.R., Rammensee, H.G., Steinle, A., Down-regulation of MICA on human tumors by proteolytic shedding (2002) J Immunol, 169, pp. 4098-4102
• Coudert, J.D., Zimmer, J., Tomasello, E., Cebecauer, M., Colonna, M., Vivier, E., Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells (2005) Blood, 106, pp. 1711-1717
• Castriconi, R., Cantoni, C., Della Chiesa, M., Vitale, M., Marcenaro, E., Conte, R., Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NKmediated killing of dendritic cells (2003) Proc Natl Acad Sci USA, 100, pp. 4120-4125
• Friese, M.A., Wischhusen, J., Wick, W., Weiler, M., Eisele, G., Steinle, A., RNA interference targeting transforming growth factor-β enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo (2004) Cancer Res, 64, pp. 7596-7603
• Waldhauer, I., Steinle, A., Proteolytic release of soluble UL16-binding protein 2 from tumor cells (2006) Cancer Res, 66, pp. 2520-2526
• Waldhauer, I., Goehlsdorf, D., Gieseke, F., Weinschenk, T., Wittenbrink, M., Ludwig, A., Tumor-associated MICA is shed by ADAM proteases (2008) Cancer Res, 68, pp. 6368-6376
• Salih, H.R., Goehlsdorf, D., Steinle, A., Release of MICB molecules by tumor cells: Mechanism and soluble MICB in sera of cancer patients (2006) Hum Immunol, 67, pp. 188-195
• Hojilla, C.V., Mohammed, F.F., Khokha, R., Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development (2003) Br J Cancer, 89, pp. 1817-1821
• Sullivan, R., Graham, C.H., Hypoxia-driven selection of the metastatic phenotype (2007) Cancer Metastasis Rev, 26, pp. 319-331
• Siemens, D.R., Hu, N., Sheikhi, A.K., Chung, E., Frederiksen, L.J., Pross, H., Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: Role of nitric oxide (2008) Cancer Res, 68, pp. 4746-4753
• Kaiser, B.K., Yim, D., Chow, I.T., Gonzalez, S., Dai, Z., Mann, H.H., Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands (2007) Nature, 447, pp. 482-486
• Cao, W., Xi, X., Hao, Z., Li, W., Kong, Y., Cui, L., RAET1E2, a Soluble Isoform of the UL16-binding Protein RAET1E Produced by Tumor Cells, Inhibits NKG2D-mediated NK Cytotoxicity (2007) J Biol Chem, 282, pp. 18922-18928
• Fuertes, M.B., Girart, M.V., Molinero, L.L., Domaica, C.I., Rossi, L.E., Barrio, M.M., Intracellular Retention of the NKG2D Ligand MHC Class I Chain-Related Gene A in Human Melanomas Confers Immune Privilege and Prevents NK Cell-Mediated Cytotoxicity (2008) J Immunol, 180, pp. 4606-4614
• Groh, V., Smythe, K., Dai, Z., Spies, T., Fas ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity (2006) Nat Immunol, 7, pp. 755-762
• Clayton, A., Mitchell, J.P., Court, J., Linnane, S., Mason, M.D., Tabi, Z., Human tumor-derived exosomes down-modulate NKG2D expression (2008) J Immunol, 180, pp. 7249-7458
• Bui, J.D., Carayannopoulos, L.N., Lanier, L.L., Yokoyama, W.M., Schreiber, R.D., IFN-dependent down-regulation of the NKG2D ligand H60 on tumors (2006) J Immunol, 176, pp. 905-913
• Schwinn, N., Vokhminova, D., Sucker, A., Textor, S., Striegel, S., Moll, I., Interferon-γ down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells (2008) Int J Cancer, 124, pp. 1594-1604
• Yadav, D., Ngolab, J., Lim, R.S., Krishnamurthy, S., Bui, J.D., Cutting edge: Down-regulation of MHC class I-related chain A on tumor cells by IFN-γ-induced microRNA (2009) J Immunol, 182, pp. 39-43
• Della Chiesa, M., Carlomagno, S., Frumento, G., Balsamo, M., Cantoni, C., Conte, R., The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function (2006) Blood, 108, pp. 4118-4125
• Lagadari, M., Lehmann, K., Ziemer, M., Truta-Feles, K., Berod, L., Idzko, M., Sphingosine-1-phosphate inhibits the cytotoxic activity of NK cells via Gs protein-mediated signalling (2009) Int J Oncol, 34, pp. 287-294
• Irigoyen, J.P., Munoz-Canoves, P., Montero, L., Koziczak, M., Nagamine, Y., The plasminogen activator system: Biology and regulation (1999) Cell Mol Life Sci, 56, pp. 104-132
• Van Den Broeck, T., Stevenaert, F., Taveirne, S., Debacker, V., Vangestel, C., Vandekerckhove, B., Ly49E-dependent inhibition of natural killer cells by urokinase plasminogen activator (2008) Blood, 112, pp. 5046-5051
• Roth, P., Mittelbronn, M., Wick, W., Meyermann, R., Tatagiba, M., Weller, M., Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1 (2007) Cancer Res, 67, pp. 3540-3544
• Stern, N., Markel, G., Arnon, T.I., Gruda, R., Wong, H., Gray-Owen, S.D., Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1 (2005) J Immunol, 174, pp. 6692-6701
• Rouas-Freiss, N., Moreau, P., Menier, C., LeMaoult, J., Carosella, E.D., Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses (2007) Semin Cancer Biol, 17, pp. 413-421
• Caumartin, J., Favier, B., Daouya, M., Guillard, C., Moreau, P., Carosella, E.D., Trogocytosis-based generation of suppressive NK cells (2007) EMBO J, 26, pp. 1423-1433
• Maki, G., Hayes, G.M., Naji, A., Tyler, T., Carosella, E.D., Rouas-Freiss, N., NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: Implication of HLA-G (2008) Leukemia, 22, pp. 998-1006
• Roda-Navarro, P., Vales-Gomez, M., Chisholm, S.E., Reyburn, H.T., Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function (2006) Proc Natl Acad Sci USA, 103, pp. 11258-11263
• Le Maux Chansac, B., Moretta, A., Vergnon, I., Opolon, P., Lecluse, Y., Grunenwald, D., NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors (2005) J Immunol, 175, pp. 5790-5798
• Li, H., Han, Y., Guo, Q., Zhang, M., Cao, X., Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β1 (2009) J Immunol, 182, pp. 240-249
• Nausch, N., Galani, I.E., Schlecker, E., Cerwenka, A., Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells (2008) Blood, 112, pp. 4080-4089
• Waldmann, T.A., Effective cancer therapy through immunomodulation (2006) Annu Rev Med, 57, pp. 65-81
• Li, M.O., Wan, Y.Y., Sanjabi, S., Robertson, A.K., Flavell, R.A., Transforming growth factor-β regulation of immune responses (2006) Annu Rev Immunol, 24, pp. 99-146
• Torre-Amione, G., Beauchamp, R.D., Koeppen, H., Park, B.H., Schreiber, H., Moses, H.L., A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance (1990) Proc Natl Acad Sci USA, 87, pp. 1486-1490
• Gorelik, L., Flavell, R.A., Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells (2001) Nat Med, 7, pp. 1118-1122
• Thomas, D.A., Massague, J., TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance (2005) Cancer Cell, 8, pp. 369-380
• Kurte, M., Lopez, M., Aguirre, A., Escobar, A., Aguillon, J.C., Charo, J., A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and transporter associated with antigen processing 1/2 in human melanoma cells (2004) J Immunol, 173, pp. 1731-1737
• Akasaki, Y., Liu, G., Chung, N.H., Ehtesham, M., Black, K.L., Yu, J.S., Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma (2004) J Immunol, 173, pp. 4352-4359
• Agrawal, B., Krantz, M.J., Reddish, M.A., Longenecker, B.M., Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 (1998) Nat Med, 4, pp. 43-49
• Mocellin, S., Marincola, F.M., Young, H.A., Interleukin-10 and the immune response against cancer: A counterpoint (2005) J Leukoc Biol, 78, pp. 1043-1051
• Lopez, M.V., Adris, S.K., Bravo, A.I., Chernajovsky, Y., Podhajcer, O.L., IL-12 and IL-10 expression synergize to induce the immunemediated eradication of established colon and mammary tumors and lung metastasis (2005) J Immunol, 175, pp. 5885-5894
• Blank, C., Gajewski, T.F., Mackensen, A., Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: Implications for tumor immunotherapy (2005) Cancer Immunol Immunother, 54, pp. 307-314
• Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation (2000) J Exp Med, 192, pp. 1027-1034
• Dong, H., Strome, S.E., Salomao, D.R., Tamura, H., Hirano, F., Flies, D.B., Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion (2002) Nat Med, 8, pp. 793-800
• Mellor, A.L., Munn, D.H., Immunology at the maternal-fetal interface: Lessons for T cell tolerance and suppression (2000) Annu Rev Immunol, 18, pp. 367-391
• Uyttenhove, C., Pilotte, L., Theate, I., Stroobant, V., Colau, D., Parmentier, N., Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase (2003) Nat Med, 9, pp. 1269-1274
• Siegel, R.M., Chan, F.K., Chun, H.J., Lenardo, M.J., The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity (2000) Nat Immunol, 1, pp. 469-474
• Sakaguchi, S., Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses (2004) Annu Rev Immunol, 22, pp. 531-562
• Zou, W., Immunosuppressive networks in the tumour environment and their therapeutic relevance (2005) Nat Rev Cancer, 5, pp. 263-274
• O'Garra, A., Vieira, P.L., Vieira, P., Goldfeld, A.E., IL-10-producing and naturally occurring CD4+ Tregs: Limiting collateral damage (2004) J Clin Invest, 114, pp. 1372-1378
• Taams, L.S., Palmer, D.B., Akbar, A.N., Robinson, D.S., Brown, Z., Hawrylowicz, C.M., Regulatory T cells in human disease and their potential for therapeutic manipulation (2006) Immunology, 118, pp. 1-9
• Zimmer, J., Andres, E., Hentges, F., NK cells and Treg cells: A fascinating dance cheek to cheek (2008) Eur J Immunol, 38, pp. 2942-2945
• Ghiringhelli, F., Menard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner (2005) J Exp Med, 202, pp. 1075-1085
• van Kooyk, Y., Rabinovich, G.A., Protein-glycan interactions in the control of innate and adaptive immune responses (2008) Nat Immunol, 9, pp. 593-601
• Rabinovich, G.A., Toscano, M.A., Turning 'sweet' on immunity: Galectin-glycan interactions in immune tolerance and inflammation (2009) Nat Rev Immunol, 9, pp. 338-352
• Rabinovich GA. Galectin-1 as a potential cancer target. British J Cancer 2005; 92: 1188-92; Matarrese, P., Tinari, A., Mormone, E., Bianco, G.A., Toscano, M.A., Ascione, B., Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission (2005) J Biol Chem, 280, pp. 6969-6985
• Chung, C.D., Patel, V.P., Moran, M., Lewis, L.A., Miceli, M.C., Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction (2000) J Immunol, 165, pp. 3722-3729
• Toscano, M.A., Commodaro, A.G., Ilarregui, J.M., Bianco, G.A., Liberman, A., Serra, H.M., Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatorymediated anti-inflammatory responses (2006) J Immunol, 176, pp. 6323-6332
• Toscano, M.A., Bianco, G.A., Ilarregui, J.M., Croci, D.O., Correale, J., Hernandez, J.D., Differential glycosylation of T(H)1, T(H)2 and T(H)-17 effector cells selectively regulates susceptibility to cell death (2007) Nat Immunol, 8, pp. 825-834
• Correa, S.G., Sotomayor, C.E., Aoki, M.P., Maldonado, C.A., Rabinovich, G., Opposite effects of galectin-1 on alternative metabolic pathways of L-arginine in resident, inflammatory, and activated macrophages (2003) Glycobiology, 13, pp. 119-128
• Barrionuevo, P., Beigier-Bompadre, M., Ilarregui, J.M., Toscano, M.A., Bianco, G.A., Isturiz, M.A., A novel function for galectin-1 at the crossroad of innate and adaptive immunity: Galectin-1 regulates monocyte/macrophage physiology through a nonapoptotic ERK-dependent pathway (2007) J Immunol, 178, pp. 436-445
• Blois, S.M., Ilarregui, J.M., Tometten, M., Garcia, M., Orsal, A.S., Cordo-Russo, R., A pivotal role for galectin-1 in fetomaternal tolerance (2007) Nat Med, 13, pp. 1450-1457
• Juszczynski, P., Ouyang, J., Monti, S., Rodig, S.J., Takeyama, K., Abramson, J., The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma (2007) Proc Natl Acad Sci USA, 104, pp. 13134-13139
• QT, L., Shi, G., Cao, H., Nelson, D.W., Wang, Y., Chen, E.Y., Galectin-1: A link between tumor hypoxia and tumor immune privilege (2005) J Clin Oncol, 23, pp. 8932-8941
• Daroqui, C.M., Ilarregui, J.M., Rubinstein, N., Salatino, M., Toscano, M.A., Vazquez, P., Regulation of galectin-1 expression by transforming growth factor β1 in metastatic mammary adenocarcinoma cells: Implications for tumor-immune escape (2007) Cancer Immunol Immunother, 56, pp. 491-499
• Zacarias Fluck, M.F., Rico, M.J., Gervasoni, S.I., Ilarregui, J.M., Toscano, M.A., Rabinovich, G.A., Low-dose cyclophosphamide modulates galectin-1 expression and function in an experimental rat lymphoma model (2007) Cancer Immunol Immunother, 56, pp. 237-248
• Peng, W., Wang, H.Y., Miyahara, Y., Peng, G., Wang, R.F., Tumor-associated galectin-3 modulates the function of tumor-reactive T cells (2008) Cancer Res, 68, pp. 7228-7236
• Klibi, J., Niki, T., Riedel, A., Pioche-Durieu, C., Souquere, S., Rubinstein, E., Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells (2009) Blood, 113, pp. 1957-1966
• Nagahara, K., Arikawa, T., Oomizu, S., Kontani, K., Nobumoto, A., Tateno, H., Galectin-9 increases Tim-3+ dendritic cells and CD8 + T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions (2008) J Immunol, 181, pp. 7660-7669
• Demotte, N., Stroobant, V., Courtoy, P.J., Van Der Smissen, P., Colau, D., Luescher, I.F., Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes (2008) Immunity, 28, pp. 414-424
• Salatino, M., Croci, D.O., Bianco, G.A., Ilarregui, J.M., Toscano, M.A., Rabinovich, G.A., Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer (2008) Expert Opin Biol Ther, 8, pp. 45-57
• Camp, R.L., Neumeister, V., Rimm, D.L., A decade of tissue microarrays: Progress in the discovery and validation of cancer biomarkers (2008) J Clin Oncol, 26, pp. 5630-5637
• Sotomayor, E.M., Borrello, I., Tubb, E., Rattis, F.M., Bien, H., Lu, Z., Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 (1999) Nat Med, 5, pp. 780-787
• Diehl, L., den Boer, A.T., Schoenberger, S.P., van der Voort, E.I., Schumacher, T.N., Melief, C.J., CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy (1999) Nat Med, 5, pp. 774-779
• Bansal-Pakala, P., Jember, A.G., Croft, M., Signaling through OX40 (CD134) breaks peripheral T-cell tolerance (2001) Nat Med, 7, pp. 907-912
• Murata, S., Ladle, B.H., Kim, P.S., Lutz, E.R., Wolpoe, M.E., Ivie, S.E., OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen (2006) J Immunol, 176, pp. 974-983
• Melief, C.J., Cancer immunotherapy by dendritic cells (2008) Immunity, 29, pp. 372-383
• Barber, A., Zhang, T., DeMars, L.R., Conejo-Garcia, J., Roby, K.F., Sentman, C.L., Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer (2007) Cancer Res, 67, pp. 5003-5008
• Barber, A., Zhang, T., Megli, C.J., Wu, J., Meehan, K.R., Sentman, C.L., Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma (2008) Exp Hematol, 36, pp. 1318-1328
• Kanzler, H., Barrat, F.J., Hessel, E.M., Coffman, R.L., Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists (2007) Nat Med, 13, pp. 552-559
• Rakoff-Nahoum, S., Medzhitov, R., Toll-like receptors and cancer (2009) Nat Rev Cancer, 9, pp. 57-63
• Salazar-Onfray, F., Lopez, M.N., Mendoza-Naranjo, A., Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape (2007) Cytokine Growth Factor Rev, 18, pp. 171-182
• Sotomayor, E.M., Borrello, I., Tubb, E., Allison, J.P., Levitsky, H.I., In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance (1999) Proc Natl Acad Sci USA, 96, pp. 11476-11481
• Phan, G.Q., Yang, J.C., Sherry, R.M., Hwu, P., Topalian, S.L., Schwartzentruber, D.J., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma (2003) Proc Natl Acad Sci USA, 100, pp. 8372-8377
• van Elsas, A., Hurwitz, A.A., Allison, J.P., Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colonystimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation (1999) J Exp Med, 190, pp. 355-366
• Leach, D.R., Krummel, M.F., Allison, J.P., Enhancement of antitumor immunity by CTLA-4 blockade (1996) Science, 271, pp. 1734-1736
• Hodi, F.S., Mihm, M.C., Soiffer, R.J., Haluska, F.G., Butler, M., Seiden, M.V., Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients (2003) Proc Natl Acad Sci USA, 100, pp. 4712-4717
• Muller, A.J., DuHadaway, J.B., Donover, P.S., Sutanto-Ward, E., Prendergast, G.C., Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy (2005) Nat Med, 11, pp. 312-319
• Turk, M.J., Guevara-Patino, J.A., Rizzuto, G.A., Engelhorn, M.E., Sakaguchi, S., Houghton, A.N., Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells (2004) J Exp Med, 200, pp. 771-782
• Shevach, E.M., Stephens, G.L., The GITR-GITRL interaction: Costimulation or contrasuppression of regulatory activity? (2006) Nat Rev Immunol, 6, pp. 613-618
• Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., Nakayama, E., Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody (1999) Cancer Res, 59, pp. 3128-3133
• Shimizu, J., Yamazaki, S., Sakaguchi, S., Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity (1999) J Immunol, 163, pp. 5211-5218
• Jinushi, M., Hodi, F.S., Dranoff, G., Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity (2006) Proc Natl Acad Sci USA, 103, pp. 9190-9195
• Fonseca, C., Soiffer, R., Ho, V., Vanneman, M., Jinushi, M., Ritz, J., Protein disulfide isomerases are antibody targets during immunemediated tumor destruction (2008) Blood, 113, pp. 1681-1688
• Katz, J.B., Muller, A.J., Prendergast, G.C., Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape (2008) Immunol Rev, 222, pp. 206-221
• Guiducci, C., Vicari, A.P., Sangaletti, S., Trinchieri, G., Colombo, M.P., Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection (2005) Cancer Res, 65, pp. 3437-3446
• Croci, D.O., Zacarias Fluck, M.F., Rico, M.J., Matar, P., Rabinovich, G.A., Scharovsky, O.G., Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment (2007) Cancer Immunol Immunother, 56, pp. 1687-1700
• David Dong, Z.M., Aplin, A.C., Nicosia, R.F., Regulation of angiogenesis by macrophages, dendritic cells, and circulating myelomonocytic cells (2009) Curr Pharm Des, 15 (4), pp. 365-379
• Louis, C.U., Brenner, M.K., Cellular immunotherapy for neuroblastoma: A review of current vaccine and adoptive T cell therapeutics (2009) Curr Pharm Des, 15 (4), pp. 424-429
• Mostbock, S., Cytokine/Antibody complexes: An emerging class of immunostimulants (2009) Curr Pharm Des, 15 (7), pp. 809-825

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------